About
Access Biotechnology, a segment of Access Industries, was founded in 2019 and is led by Liam Ratcliffe, former head of worldwide clinical R&D at Pfizer. They focus on investing in both private and public biopharma companies at various development stages, from discovery to latestage clinical programs. Their approach emphasizes longterm orientation, adaptability, technical rigor, and collaboration. They have a portfolio of over 30 investments, with more than 5 exits. Notable investments include Disc Medicine, Eliem Therapeutics, Day One Biopharmaceuticals, Perfuse Therapeutics, Nimbus Therapeutics, and many others.